Home / Companies / News / FabiFlu cheaper than other drugs to treat Covid-19, claims Glenmark

FabiFlu cheaper than other drugs to treat Covid-19, claims Glenmark

The company further claimed that since favipiravir was an oral therapy, patients could be treated on an out-patient basis without incurring additional hospitalisation expenses

covid, coronavirus, vaccine, drug, pharma, medicine, cure

Premium

The company said it has developed the active pharmaceutical ingredient in-house for FabiFlu, and till date remains the only company in India to have conducted a randomised controlled clinical trial for favipiravir.

Sohini Das Mumbai

4 min read Last Updated : Jul 21 2020 | 11:16 PM IST

Glenmark on Tuesday said FabiFlu — its generic version of oral antiviral drug favipiravir — is cheaper than other drugs, including remdesivir, tocilizumab, itolizumab, etc, approved for emergency use for the treatment of Covid-19.

The Mumbai-based firm was responding to the Drugs Controller General of India’s (DCGI) letter seeking clarification over its alleged ‘false claims’ on FabiFlu’s efficacy on Covid-19 patients with comorbidities and high price of the drug, after a legislator raised these issues in a letter to Health Minister Harsh Vardhan.

Glenmark said these were “careless, unsubstantiated allegations devoid of merits”.

On Tuesday, Glenmark’s shares ended the day’s trade at Rs

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in